Table 2 Studies assessing clinical cardioprotective effects of GLP1Ra by Cardiac Magnetic Resonance
Study | Heart Failure | Diabetes | GLP-1Ra | Duration of therapy | Results | ||
|---|---|---|---|---|---|---|---|
Del Blanco et al. [151] | No | No | Exenatide | Premedication before revascularization | No changes in infarct size measured by LGE, myocardial salvage index, transmurality index, LVEF and MVO | ||
Lønborg et al. [157] | No | No | Exenatide | 15 min before intervention-6 h after the procedure | Increased myocardial salvage index and reduced infarcted size | ||
Chen et al. [152] | HFrEF | Yes | Exenatide | 26 weeks | No improvement in LV function, structure, adiposity, and diffuse fibrosis | ||
Nozue et al. [153] | No | No | Liraglutide | 6 months | Prevention of the progression of LV remodeling | ||
Bizino et al. [158] | No | Yes | Liraglutide | 26 weeks | Reduction of diastolic and systolic function | ||
Dutour et al. [155] | No | Yes | Exenatide | 26 weeks | EAT reduction | ||
Zhao et al. [116] | No | Yes | Liraglutide | 3 months | EAT reduction | ||
Bizino et al. [154] | No | Yes | Liraglutide | 26 weeks | No changes in EAT and myocardial triacylglycerol content | ||